Anixa Biosciences (ANIX) Other Accumulated Expenses (2011 - 2026)
Anixa Biosciences' (ANIX) quarterly Other Accumulated Expenses came in at $626000.0 in Q2 2026, little changed YoY from $626000.0 in Q2 2025, and little changed on a QoQ basis from $626000.0 in Q4 2025.
Anixa Biosciences (ANIX) Other Accumulated Expenses (2011 - 2026) Analysis & Trends
Anixa Biosciences (ANIX) has 14 years of Other Accumulated Expenses data on file, last reported at $626000.0 in Q2 2026.
- Quarterly Other Accumulated Expenses changed 0.0% year-over-year to $626000.0 in Q2 2026, while the trailing twelve-month figure through Apr 2026 was $626000.0 (changed 0.0% YoY) and the FY2025 annual result came in at $626000.0, changed 0.0% from the prior year.
- Other Accumulated Expenses steadied at $626000.0 in Q2 2026, from $626000.0 in the prior quarter.
- In the past five years, Other Accumulated Expenses ranged from a high of $626000.0 in Q4 2023 to a low of $626000.0 in Q4 2023.
- A 4-year average of $626000.0 and a median of $626000.0 in 2023 frame the typical range for Other Accumulated Expenses.
- The widest YoY moves for Other Accumulated Expenses: up 0.0% in 2024, down 0.0% in 2024.
- Tracing ANIX's Other Accumulated Expenses over 4 years: stood at $626000.0 in 2023, then changed by 0.0% to $626000.0 in 2024, then changed by 0.0% to $626000.0 in 2025, then changed by 0.0% to $626000.0 in 2026.
- The last three Other Accumulated Expenses figures came in at $626000.0 (Q2 2026), $626000.0 (Q4 2025), and $626000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Anixa Biosciences | 123.62 Mn | 123.62 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 626,000.00 |
| Oct 31, 2025 | 626,000.00 |
| Jul 31, 2025 | 626,000.00 |
| Apr 30, 2025 | 626,000.00 |
| Jan 31, 2025 | 626,000.00 |
| Oct 31, 2024 | 626,000.00 |
| Jul 31, 2024 | 626,000.00 |
| Oct 31, 2023 | 626,000.00 |
| Apr 30, 2020 | 9,104.00 |
| Jan 31, 2020 | 27,819.00 |
| Oct 31, 2019 | 1,247.00 |
| Jul 31, 2019 | 9,459.00 |
| Apr 30, 2019 | 17,690.00 |
| Jan 31, 2019 | 366,670.00 |
| Oct 31, 2018 | 65,964.00 |
| Jul 31, 2018 | 366,670.00 |
| Apr 30, 2018 | 246,177.00 |
| Jan 31, 2018 | 108,811.00 |
| Oct 31, 2017 | 119,963.00 |
| Jul 31, 2017 | 60,260.00 |